Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis

Table 1 General characteristic of the included studies

Ref.	Location	Study	Surgical indication	Comparator	Control	Number of patients		Age of patients (yr)		Sex (M/F)		Follow up
						Comparator	Control	Comparator	Control	Comparator	Control
Jespersen et al[32], 2019	Denmark	RCT	Spondylolisthesis	Teriparatide	Placebo	41	46	71	70	11/30	7/39	12 mo
Sheng et al[37], 2018	China	RCT	Spondylolisthesis HIVD, spinal stenosis	Zoledronic acid	Placebo	28	28	60.7	63.1	7/21	10/18	12 mo
Ide et al[31], 2018	Japan	RCT	Spinal stenosis	Teriparatide + denosumab	Teriparatide	8	8	73.2	75.0	3/5	0/8	12 mo
Seki et al[36], 2017	Japan	Prospective	Vertebral fracture	Teriparatide	Alendronate/risedronate	33	25	72.5	71.5	0/33	0/25	24 mo
Ebata et al[30], 2017	Japan	RCT	Lumbar degenerative disease	Teriparatide	Placebo	36	38	72.6	70.4	0/36	0/38	6 mo
Cho et al[29], 2017	Korea	Prospective	Spinal stenosis, spondylolisthesis	Teriparatide	Alendronate	23	24	71.0	68.2	0/23	0/24	24 mo
Yagi et al[39], 2016	Japan	Prospective	Posterior long instrumented fusion	Teriparatide	Placebo	43	33	68.6	66.7	0/43	0/33	24 mo
Chen et al[28], 2016	China	RCT	Spondylolisthesis	zoledronic acid	Placebo	33	36	65	63	6/27	7/29	12 mo
Ohtori et al[35], 2013	Japan	RCT	Spondylolisthesis with spinal stenosis	Teriparatide/Risedronate	Placebo	20/20	20	78/75	73	0/20,0/20	0/22	12 mo
Li et al[33], 2012	China	RCT	Non-specific	Zoledronic acid	Placebo	28	25	63.63	63.83	13/28	16/25	12 mo
Nagahama et al[34], 2011	Japan	RCT	Spondylolisthesis and spinal enosis	Alendronate	Placebo	19	17	70.3	67.4	1/18	1/16	12 mo
Wang et al[40], 2021	China	RCT	Transforaminal lumbar interbody fusion	Teriparatide	Zoledronic acid	29	38	66.34	65.89	4/25	3/35	12 mo

RCT: Randomized controlled trials; HIVD: Herniated intervertebral disc.